Peripheral Arterial Disease Concept

subject area of

• A MultiCenter Pilot Randomized Controlled Trial of Remote Ischemic Preconditioning in Major Vascular Surgery  Journal Articles
• A National Canadian Survey of Antithrombotic Therapy After Urgent and Emergent Limb Revascularization  Journal Articles
• Anticoagulation therapy in 2015: where we are and where we are going  Journal Articles
• Antithrombotic Agents  Journal Articles
• Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement.  Journal Articles
• Antithrombotic Therapy for Peripheral Artery Disease  Journal Articles
• Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making  Journal Articles
• Antithrombotics in stable peripheral artery disease  Journal Articles
• Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study  Journal Articles
• Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus  Journal Articles
• Assessing Limb Outcomes in Drug Trials in Peripheral Artery Disease: The Need for a Universal and Pragmatic Definition  Journal Articles
• Association Between Mental Health Burden, Clinical Presentation, and Outcomes in Individuals With Symptomatic Peripheral Artery Disease: A Scientific Statement From the American Heart Association  Journal Articles
• Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review  Journal Articles
• Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis  Journal Articles
• Building Your Peripheral Artery Disease Toolkit: Medical Management of Peripheral Artery Disease in 2022  Journal Articles
• COMPASS for Vascular Surgeons  Journal Articles
• Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease  Journal Articles
• Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up  Journal Articles
• Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease  Journal Articles
• Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk  Journal Articles
• Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1  Journal Articles
• Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial  Journal Articles
• Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease  Journal Articles
• Consensus Document on Intermittent Claudication from the Central European Vascular Forum (C.E.V.F.)-3rd revision (2013) with the sharing of the Mediterranean League of Angiology and Vascular Surgery, and the North Africa and Middle East Chapter of International Union of Angiology.  Journal Articles
• Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial  Journal Articles
• Diet and Nutrition in Peripheral Artery Disease: A Systematic Review  Journal Articles
• Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort  Journal Articles
• Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence  Journal Articles
• Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances  Journal Articles
• Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial  Journal Articles
• Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial  Journal Articles
• Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes  Journal Articles
• Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD  Journal Articles
• Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease  Journal Articles
• Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD  Journal Articles
• Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease  Journal Articles
• External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry  Journal Articles
• External applicability of the COMPASS trial: the Western Denmark Heart Registry  Journal Articles
• Genetic drivers of heterogeneity in type 2 diabetes pathophysiology  Journal Articles
• Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia  Journal Articles
• Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease  Journal Articles
• Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease  Journal Articles
• How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?  Journal Articles
• Identifying and Treating Young Patients at Risk for Cardiovascular Events  Journal Articles
• Identifying the highest risk vascular patients: Insights from the XATOA registry  Journal Articles
• Impact of Arterial Procedures on Coagulation and Fibrinolysis – A Pilot Study  Journal Articles
• Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD  Journal Articles
• Inclusion of People With Peripheral Artery Disease in Cardiac Rehabilitation Programs: A Pan-Canadian Survey  Journal Articles
• Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease  Journal Articles
• Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy  Journal Articles
• Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48  Journal Articles
• Leukotrienes biosynthesis in vascular surgery patients during perioperative period.  Journal Articles
• Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial  Journal Articles
• Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD  Journal Articles
• Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization.  Journal Articles
• Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials  Journal Articles
• Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial  Journal Articles
• Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease  Journal Articles
• Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin  Journal Articles
• Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD  Journal Articles
• Microvascular disease increases the risk of lower limb amputation – A Western Danish cohort study  Journal Articles
• Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease  Journal Articles
• Myocardial injury after endovascular revascularization in critical limb ischemia predicts 1-year mortality: a prospective observational cohort study  Journal Articles
• New developments in anticoagulants: Past, present and future  Journal Articles
• Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia  Journal Articles
• Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry  Journal Articles
• Patients with Peripheral Artery Disease in the COMPASS Trial  Journal Articles
• Perioperative cardiovascular complications rate and activity of coagulation and fibrinolysis among patients undergoing vascular surgery for peripheral artery disease and abdominal aortic aneurysm  Journal Articles
• Perioperative management and outcomes in patients receiving low-dose rivaroxaban and/or aspirin: a subanalysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial  Journal Articles
• Peripheral Artery Disease: A High-Risk Yet Understudied, Underdiagnosed, and Undertreated Condition—A Call to Action  Journal Articles
• Prevention and Management of Urgent/Emergent Limb Ischemia  Journal Articles
• Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone  Journal Articles
• Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)  Journal Articles
• Review of aspirin and clopidogrel resistance in peripheral arterial disease  Journal Articles
• Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial  Journal Articles
• Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis  Journal Articles
• Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD  Journal Articles
• Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction  Journal Articles
• Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease  Journal Articles
• Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease  Journal Articles
• Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization  Journal Articles
• Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios  Journal Articles
• Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization  Journal Articles
• Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial  Journal Articles
• Rivaroxaban for Patients with Intermittent Claudication.  Journal Articles
• Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease  Journal Articles
• Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment  Journal Articles
• Rivaroxaban in Peripheral Artery Disease after Revascularization  Journal Articles
• Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits  Journal Articles
• Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial  Journal Articles
• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial  Journal Articles
• Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization  Journal Articles
• Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin  Journal Articles
• Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD  Journal Articles
• Social Deprivation and Peripheral Artery Disease  Journal Articles
• Strategies to reduce out-of-pocket medication costs for Canadians with peripheral arterial disease  Journal Articles
• Stroke Outcomes in the COMPASS Trial  Journal Articles
• Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease  Journal Articles
• The Association of Cannabis Use Disorder with Acute Limb Ischemia and Critical Limb Ischemia  Journal Articles
• The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective  Journal Articles
• The Time Has Come for Vascular Medicine in Canada  Journal Articles
• The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial  Journal Articles
• The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era  Journal Articles
• The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial  Journal Articles
• The use of local anesthesia to perform lower limb revascularization in the fragile patient with critical limb ischemia.  Journal Articles
• Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study  Journal Articles
• Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial  Journal Articles
• Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial  Journal Articles
• Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD  Conferences
• Urinary cysteinyl leukotrienes in one-year follow-up of percutaneous transluminal angioplasty for peripheral arterial occlusive disease  Journal Articles
• Urinary fatty acid binding protein 3 (uFABP3) is a potential biomarker for peripheral arterial disease  Journal Articles
• Vorapaxar in the Secondary Prevention of Atherothrombotic Events  Journal Articles
• Women and Peripheral Arterial Disease: A Review of Sex Differences in Epidemiology, Clinical Manifestations, and Outcomes  Journal Articles
• Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both  Journal Articles
• miR-29c-3p is an Effective Biomarker of Abdominal Aortic Aneurysm in Patients Undergoing Elective Surgery  Journal Articles